Nurix director granted 31,250 stock options

Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock.

Rhea-AI Filing Summary

Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and are held directly. Following this award, he holds options on 31,250 shares.

The option grant vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if he continues providing service to Nurix on that vesting date. The options expire on May 14, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 31,250 shares

Grant/Award 1 txn

Insider Lacey David L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Options granted: 31,250 shares Exercise price: $15.86 per share Post-grant option holdings: 31,250 shares +2 more

5 metrics

Options granted 31,250 shares Director stock option grant

Exercise price $15.86 per share Conversion or exercise price of options

Post-grant option holdings 31,250 shares Total options beneficially owned after transaction

Vesting deadline May 15, 2027 Latest date for 100% vesting, subject to service

Expiration date May 14, 2036 Option term end date if unexercised

Key Terms

Director Stock Option (right to buy), conversion or exercise price, vesting, annual meeting of the Issuer's stockholders, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 15.8600"

vesting financial

"The stock option vests as to 100% of the award on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders"

expiration date financial

"expiration_date: 2036-05-14T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nurix Therapeutics (NRIX) report for David L. Lacey?

Nurix Therapeutics reported that director David L. Lacey received a grant of 31,250 stock options. These options give him the right to buy common shares at a fixed price and represent compensation rather than an open-market share purchase or sale.

What is the exercise price of David L. Lacey’s new Nurix (NRIX) stock options?

The newly granted options to David L. Lacey have an exercise price of $15.86 per share. This is the fixed price at which he can purchase Nurix common stock if he chooses to exercise the options before they expire.

When do David L. Lacey’s Nurix (NRIX) stock options vest?

The stock options vest 100% on the earlier of the next annual stockholder meeting or May 15, 2027. Vesting is conditioned on Lacey continuing to provide service to Nurix on the applicable vesting date, according to the filing footnote.

When do David L. Lacey’s Nurix (NRIX) stock options expire?

The options granted to David L. Lacey are scheduled to expire on May 14, 2036. If the options are not exercised by that expiration date, the right to purchase Nurix common shares at the $15.86 exercise price will lapse.

How many Nurix (NRIX) options does David L. Lacey hold after this grant?

After this grant, David L. Lacey holds stock options for 31,250 shares of Nurix common stock. This total reflects the options reported in the filing as beneficially owned following the transaction, all held in a direct ownership capacity.

Is David L. Lacey’s Nurix (NRIX) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant or award acquisition of stock options, not an open-market purchase or sale of shares. The transaction code is “A,” indicating compensation-related options, with no cash market trade in Nurix common stock disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lacey David L.

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		(1)	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for David L. Lacey	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)